跳至主要内容
临床试验/NCT02084511
NCT02084511已完成1 期

Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain (a Single-centre, Partially Double-blinded, Randomised, placebo-and Active Comparator-controlled, Single-dose, Parallel-group Study)

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2014年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
80
试验地点
1
主要终点
SPID0-8h

研究概览

简要总结

To investigate the effectiveness of BI 1026706 powder for reconstitution of an oral solution compared to placebo and the relative effectiveness compared to Celecoxib.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

BI 1026706 low dose

Experimental

BI 1026706 low dose

干预措施: Placebo to BI 1026706 solution (Drug)

BI 1026706 low dose

Experimental

BI 1026706 low dose

干预措施: BI 1026706 (Drug)

BI 1026706 low dose

Experimental

BI 1026706 low dose

干预措施: Placebo to BI 1026706 tablet (Drug)

BI 1026706 high dose

Experimental

BI 1026706 high dose

干预措施: BI 1026706 (Drug)

BI 1026706 high dose

Experimental

BI 1026706 high dose

干预措施: Placebo to BI 1026706 tablet (Drug)

Placebo reference

Experimental

Placebo reference

干预措施: Placebo to BI 1026706 solution (Drug)

Placebo reference

Experimental

Placebo reference

干预措施: Placebo to BI 1026706 tablet (Drug)

Celecoxib reference

Experimental

Celecoxib capsule

干预措施: Placebo to BI 1026706 solution (Drug)

Celecoxib reference

Experimental

Celecoxib capsule

干预措施: Celecoxib (Drug)

结局指标

主要结局

SPID0-8h

时间窗: up to 8 hours post drug administration

Time-weighted sum of pain intensity difference (PID) from 0 to 8 hours post drug administration (SPID0-8h). SPID0-8h: possible range (-400; 800). The greater SPID0-8 the greater the reduction of pain intensity over the first 8 hours post drug administration.

次要结局

  • Time to Meaningful Pain Relief(up to 10 hours post drug administration)
  • Time to First Dose of Rescue Medication(up to 10 hours post drug administration)
  • SPID0-2h(up to 2 hours post drug administration)
  • Percentage of Patients With Drug-related Adverse Events(From first drug administration until 3 days after last drug administration, upto 4 days)
  • TOTPAR0-8h(up to 8 hours post drug administration)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验